公开(公告)号：US20180072710A1

公开(公告)日：2018-03-15

申请号：US15495019

申请日：2017-04-24

Applicant: SURFACE LOGIX, INC.

Inventor： Alessandra Bartolozzi ,  Stewart Campbell ,  Hope Foudoulakis ,  Brian Kirk ,  Siya Ram ,  Paul Sweetnam ,  Hemalatha Seshardri

IPC: C07D413/14 ,  C07D405/14 ,  B82Y30/00 ,  C07D403/12 ,  C07D401/14 ,  C07D403/14

CPC classification number: C07D413/14 ,  B82Y30/00 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.

公开(公告)号：US20190177311A1

公开(公告)日：2019-06-13

申请号：US16040245

申请日：2018-07-19

Applicant: SURFACE LOGIX, INC.

Inventor： Alessandra Bartolozzi ,  Stewart Campbell ,  Hope Foudoulakis ,  Brian Kirk ,  Siya Ram ,  Paul Sweetnam ,  Hemalatha Seshardri

IPC: C07D413/14 ,  C07D405/14 ,  C07D403/14 ,  B82Y30/00 ,  C07D401/14 ,  C07D403/12

Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.

公开(公告)号：US09440961B2

公开(公告)日：2016-09-13

申请号：US14581746

申请日：2014-12-23

Applicant: SURFACE LOGIX, INC.

Inventor： Alessandra Bartolozzi ,  Stewart Campbell ,  Hope Foudoulakis ,  Brian Kirk ,  Siya Ram ,  Paul Sweetnam ,  Hemalatha Seshadri

IPC: C07D413/14 ,  B82Y30/00 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

CPC classification number: C07D413/14 ,  B82Y30/00 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.

Abstract translation: 本发明涉及ROCK1和ROCK2的抑制剂以及调节这些化合物的药代动力学和/或药效学性质的方法。 还提供了抑制可用于治疗疾病的ROCK1和/或ROCK2的方法。

公开(公告)号：US08853394B2

公开(公告)日：2014-10-07

申请号：US13708420

申请日：2012-12-07

Applicant: Surface Logix, Inc.

Inventor： Stewart Campbell ,  David Duffy ,  Michael Grogan ,  Steven Kates ,  Emanuele Ostuni ,  Olivier Schueller ,  Paul Sweetnam

IPC: C07D487/04 ,  A61K31/53 ,  A61P9/02 ,  A61P15/10

CPC classification number: C07D487/04

Abstract: A compound of formula A having improved non-specific binding characteristics and pharmacokinetic properties is provided: or a pharmaceutically acceptable salt, stereoisomer, or hydrate thereof.

Abstract translation: 提供具有改善的非特异性结合特征和药代动力学性质的式A化合物：或其药学上可接受的盐，立体异构体或其水合物。

公开(公告)号：US08916576B2

公开(公告)日：2014-12-23

申请号：US13715644

申请日：2012-12-14

Applicant: Surface Logix, Inc.

Inventor： Alessandra Bartolozzi ,  Stewart Campbell ,  Hope Foudoulakis ,  Brian Kirk ,  Siya Ram ,  Paul Sweetnam ,  Hemalatha Seshadri

IPC: A01N43/54 ,  A61K31/517 ,  C07D403/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  C07D403/12 ,  B82Y30/00

CPC classification number: C07D413/14 ,  B82Y30/00 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.

Abstract translation: 本发明涉及ROCK1和ROCK2的抑制剂以及调节这些化合物的药代动力学和/或药效学性质的方法。 还提供抑制可用于治疗疾病的ROCK1和/或ROCK2的方法。

公开(公告)号：US20130096114A1

公开(公告)日：2013-04-18

申请号：US13708420

申请日：2012-12-07

Applicant: SURFACE LOGIX, INC.

Inventor： Stewart Campbell ,  David Duffy ,  Michael Grogan ,  Steven Kates ,  Emanuele Ostuni ,  Olivier Schueller ,  Paul Sweetnam

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: A compound of formula A having improved non-specific binding characteristics and pharmacokinetic properties is provided: or a pharmaceutically acceptable salt, stereoisomer, or hydrate thereof.

Abstract translation: 提供具有改善的非特异性结合特征和药代动力学性质的式A化合物：或其药学上可接受的盐，立体异构体或其水合物。